Assessment of [
Alzheimer’s disease
Four-repeat tauopathies
Image derived input function
Tau
[18F]PI-2620 quantification
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
08 May 2024
08 May 2024
Historique:
received:
15
09
2023
accepted:
01
05
2024
medline:
8
5
2024
pubmed:
8
5
2024
entrez:
8
5
2024
Statut:
aheadofprint
Résumé
[ In the first part of the study, we validated AIF derived from radial artery whole blood against IDIF by investigating 20 subjects (ten controls and ten patients). IDIF were generated by manual extraction of the carotid artery using the average and the five highest (max5) voxel intensity values and by automated extraction of the carotid artery using the average and the maximum voxel intensity value. In the second part of the study, IDIF quantification using the IDIF with the closest match to the AIF was transferred to group comparison of a large independent cohort of 40 subjects (15 healthy controls, 15 PSP patients and 10 AD patients). We compared V AIF and IDIF showed highly correlated input curves for all applied IDIF extraction methods (0.78 < r < 0.83, all p < 0.0001; area under the curves (AUC): 0.73 < r ≤ 0.82, all p ≤ 0.0003). Regarding the V Blood-free IDIF is a promising approach for quantification of [
Identifiants
pubmed: 38717592
doi: 10.1007/s00259-024-06741-7
pii: 10.1007/s00259-024-06741-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Bundesministerium für Bildung und Forschung
ID : 01EK1605A HitTau
Organisme : Deutsche Forschungsgemeinschaft
ID : EXC 2145 SyNergy - ID 390857198)
Informations de copyright
© 2024. The Author(s).
Références
Mueller A, Bullich S, Barret O, et al. Tau PET imaging with 18F-PI-2620 in patients with Alzheimer disease and healthy controls: a first-in-humans study. J Nucl Med. 2020;61:911–9.
doi: 10.2967/jnumed.119.236224
pubmed: 31712323
pmcid: 7262222
Brendel M, Barthel H, van Eimeren T, et al. Assessment of 18F-PI-2620 as a biomarker in progressive supranuclear palsy. JAMA Neurol. 2020;77:1408–19.
doi: 10.1001/jamaneurol.2020.2526
pubmed: 33165511
Palleis C, Brendel M, Finze A, et al. Cortical [18F] PI-2620 Binding Differentiates Corticobasal Syndrome Subtypes. Mov Disord. 2021;36:2104–15.
doi: 10.1002/mds.28624
pubmed: 33951244
Song M, Scheifele M, Barthel H, et al. Feasibility of short imaging protocols for [18 F] PI-2620 tau-PET in progressive supranuclear palsy. Eur J Nucl Med Mol Imaging. 2021;48:3872–85.
doi: 10.1007/s00259-021-05391-3
pubmed: 34021393
pmcid: 8484138
Song M, Beyer L, Kaiser L, et al. Binding characteristics of [18F] PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET. J Cereb Blood Flow Metab. 2021;41:2957–72.
doi: 10.1177/0271678X211018904
pubmed: 34044665
pmcid: 8545042
Künze G, Kümpfel R, Rullmann M, et al. Molecular Simulations Reveal Distinct Energetic and Kinetic Binding Properties of [18F] PI-2620 on Tau Filaments from 3R/4R and 4R Tauopathies. ACS Chem Neurosci. 2022;13:2222–34.
doi: 10.1021/acschemneuro.2c00291
pubmed: 35762647
Franzmeier N, Brendel M, Beyer L, et al. Tau deposition patterns are associated with functional connectivity in primary tauopathies. Nat Commun. 2022;13:1362.
doi: 10.1038/s41467-022-28896-3
pubmed: 35292638
pmcid: 8924216
Kovacs GG, Lukic MJ, Irwin DJ, et al. Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathol. 2020;140:99–119.
doi: 10.1007/s00401-020-02158-2
pubmed: 32383020
pmcid: 7360645
Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32:853–64.
doi: 10.1002/mds.26987
pubmed: 28467028
pmcid: 5516529
Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14:535–62.
doi: 10.1016/j.jalz.2018.02.018
pubmed: 29653606
Chételat G, Arbizu J, Barthel H, et al. Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer’s disease and other dementias. Lancet Neurol. 2020;19:951–62.
doi: 10.1016/S1474-4422(20)30314-8
pubmed: 33098804
Sevigny J, Suhy J, Chiao P, et al. Amyloid PET screening for enrichment of early-stage Alzheimer disease clinical trials. Alzheimer Dis Assoc Disorders. 2016;30:1–7.
doi: 10.1097/WAD.0000000000000144
Völter F, Beyer L, Eckenweber F, et al. Assessment of perfusion deficit with early phases of [18F] PI-2620 tau-PET versus [18F] flutemetamol-amyloid-PET recordings. Eur J Nuclear Med Molec Imaging. 2023;50:1384–94.
doi: 10.1007/s00259-022-06087-y
Daerr S, Brendel M, Zach C, et al. Evaluation of early-phase [18F]-florbetaben PET acquisition in clinical routine cases. NeuroImage: Clinical. 2017;14:77–86.
doi: 10.1016/j.nicl.2016.10.005
pubmed: 28138429
Zanotti-Fregonara P, Liow J-S, Comtat C, et al. Image-derived input function in PET brain studies: blood-based methods are resistant to motion artifacts. Nucl Med Commun. 2012;33:982–9.
doi: 10.1097/MNM.0b013e328356185c
pubmed: 22760300
pmcid: 3788705
Kuttner S, Wickstrøm KK, Lubberink M, et al. Cerebral blood flow measurements with 15O-water PET using a non-invasive machine-learning-derived arterial input function. J Cereb Blood Flow Metab. 2021;41:2229–41.
doi: 10.1177/0271678X21991393
pubmed: 33557691
pmcid: 8392760
Brendel M, Wagner L, Levin J, et al. Perfusion-phase [18F] THK5351 Tau-PET imaging as a surrogate marker for neurodegeneration. J Alzheimer’s Dis Reports. 2017;1:109–13.
doi: 10.3233/ADR-170023
Logan J, Fowler JS, Volkow ND, et al. Graphical analysis of reversible radioligand binding from time—activity measurements applied to [N-11C-methyl]-(−)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10:740–7.
doi: 10.1038/jcbfm.1990.127
pubmed: 2384545
Keuken M, Bazin P-L, Backhouse K, et al. Effects of aging on T_ 1 T 1, T_ 2^* T 2∗, and QSM MRI values in the subcortex. Brain Struct Funct. 2017;222:2487–505.
doi: 10.1007/s00429-016-1352-4
pubmed: 28168364
pmcid: 5541117
Fan L, Li H, Zhuo J, et al. The human brainnetome atlas: a new brain atlas based on connectional architecture. Cereb Cortex. 2016;26:3508–26.
doi: 10.1093/cercor/bhw157
pubmed: 27230218
pmcid: 4961028
Hammers A, Allom R, Koepp MJ, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp. 2003;19:224–47.
doi: 10.1002/hbm.10123
pubmed: 12874777
pmcid: 6871794
Williams DR, Holton JL, Strand C, et al. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson’s syndrome. Brain. 2007;130:1566–76.
doi: 10.1093/brain/awm104
pubmed: 17525140
López-González FJ, Paredes-Pacheco J, Thurnhofer-Hemsi K, et al. QModeling: a multiplatform, easy-to-use and open-source toolbox for PET kinetic analysis. Neuroinformatics. 2019;17:103–14.
doi: 10.1007/s12021-018-9384-y
pubmed: 29956130
Rullmann M, Brendel M, Schroeter ML, et al. Multicenter 18F-PI-2620 PET for in vivo Braak staging of tau pathology in Alzheimer’s disease. Biomolecules. 2022;12:458.
doi: 10.3390/biom12030458
pubmed: 35327650
pmcid: 8946049
Sari H, Erlandsson K, Law I, et al. Estimation of an image derived input function with MR-defined carotid arteries in FDG-PET human studies using a novel partial volume correction method. J Cereb Blood Flow Metab. 2017;37:1398–409.
doi: 10.1177/0271678X16656197
pubmed: 27342321
Galovic M, Erlandsson K, Fryer TD, et al. Validation of a combined image derived input function and venous sampling approach for the quantification of [18F] GE-179 PET binding in the brain. Neuroimage. 2021;237: 118194.
doi: 10.1016/j.neuroimage.2021.118194
pubmed: 34023451
Mourik JE, Lubberink M, Klumpers UM, et al. Partial volume corrected image derived input functions for dynamic PET brain studies: methodology and validation for [11C] flumazenil. Neuroimage. 2008;39:1041–50.
doi: 10.1016/j.neuroimage.2007.10.022
pubmed: 18042494
Saint-Aubert L, Lemoine L, Chiotis K, et al. Tau PET imaging: present and future directions. Mol Neurodegener. 2017;12:1–21.
doi: 10.1186/s13024-017-0162-3
Bullich S, Barret O, Constantinescu C, et al. Evaluation of dosimetry, quantitative methods, and test–retest variability of 18F-PI-2620 PET for the assessment of tau deposits in the human brain. J Nucl Med. 2020;61:920–7.
doi: 10.2967/jnumed.119.236240
pubmed: 31712324
pmcid: 7262221
Ando S, Kanazawa M, Onodera OJJoMD. Progressive supranuclear palsy with predominant cerebellar ataxia. J Movement Disorders. 2020;13:20.
doi: 10.14802/jmd.19061
Sepulveda-Falla D, Matschke J, Bernreuther C, et al. Deposition of hyperphosphorylated tau in cerebellum of PS1 E280A Alzheimer’s disease. Brain Pathol. 2011;21:452–63.
doi: 10.1111/j.1750-3639.2010.00469.x
pubmed: 21159009
pmcid: 8094246
van Berckel BN, Ossenkoppele R, Tolboom N, et al. Longitudinal amyloid imaging using 11C-PiB: methodologic considerations. J Nucl Med. 2013;54:1570–6.
doi: 10.2967/jnumed.112.113654
pubmed: 23940304